AegirBio AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AEGIR.ST research report →
Companyaegirbio.com
AegirBio AB (publ), a diagnostic company, develops and commercializes tests to follow the dosage of biological drugs. The company focuses on therapeutic drug monitoring of biologic therapies in the multiple sclerosis, cancer, and autoimmune diseases. It offers moNATor, a first dose-monitoring laboratory test to test multiple sclerosis for healthcare professionals and patients; and Viraspec, a COVID-19 saliva test kit.
- CEO
- Marco Wititteveen
- IPO
- 2020
- Employees
- 14
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $15.43M
- P/E
- -0.78
- P/S
- 0.00
- P/B
- 0.22
- EV/EBITDA
- -1.97
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 5.75%
- Op Margin
- -221.03%
- Net Margin
- -200.93%
- ROE
- -64.37%
- ROIC
- -17.05%
Growth & Income
- Revenue
- $92.00K · -94.61%
- Net Income
- $-59,696,000 · 83.55%
- EPS
- $-2.38 · 87.41%
- Op Income
- $-56,158,000
- FCF YoY
- 3.13%
Performance & Tape
- 52W High
- $1.80
- 52W Low
- $0.39
- 50D MA
- $0.52
- 200D MA
- $0.79
- Beta
- 2.75
- Avg Volume
- 371.43K
Get TickerSpark's AI analysis on AEGIR.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AEGIR.ST Coverage
We haven't published any research on AEGIR.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AEGIR.ST Report →